A
A. Pieter Kappetein
Researcher at Erasmus University Rotterdam
Publications - 86
Citations - 11000
A. Pieter Kappetein is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Percutaneous coronary intervention & Conventional PCI. The author has an hindex of 35, co-authored 86 publications receiving 9546 citations.
Papers
More filters
Journal ArticleDOI
Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
Patrick W. Serruys,Marie-Claude Morice,A. Pieter Kappetein,Antonio Colombo,David R. Holmes,Michael J. Mack,Elisabeth Ståhle,Ted Feldman,Marcel van den Brand,Eric Bass,Nic Van Dyck,Katrin Leadley,Keith D. Dawkins,Friedrich W. Mohr,Boston Scientif +14 more
TL;DR: CABG remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with PCI, resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events at 1 year.
Journal ArticleDOI
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease
Gregg W. Stone,Joseph F. Sabik,Patrick W. Serruys,Charles A. Simonton,Philippe Généreux,John D. Puskas,David E. Kandzari,Marie Claude Morice,Nicholas Lembo,W. Morris Brown,David P. Taggart,Adrian P. Banning,Béla Merkely,Ferenc Horkay,Piet W. Boonstra,Ad J. van Boven,Imre Ungi,Gábor Bogáts,Samer Mansour,Nicolas Noiseux,Manel Sabaté,José L. Pomar,Mark Hickey,Anthony H. Gershlick,Paweł Buszman,Andrzej Bochenek,Erick Schampaert,Pierre Pagé,Ovidiu Dressler,Ioanna Kosmidou,Roxana Mehran,Stuart J. Pocock,A. Pieter Kappetein +32 more
TL;DR: In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years.
Journal ArticleDOI
2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement
David R. Holmes,Michael J. Mack,Sanjay Kaul,Arvind K. Agnihotri,Karen P. Alexander,Steven R. Bailey,John H. Calhoon,Blase A. Carabello,Milind Y. Desai,Fred H. Edwards,Gary S. Francis,Timothy J. Gardner,A. Pieter Kappetein,Jane A. Linderbaum,Chirojit Mukherjee,Debabrata Mukherjee,Catherine M Otto,Carlos E. Ruiz,Ralph L. Sacco,Donnette Smith,James D. Thomas +20 more
TL;DR: The 2017-18 FACC curriculum was designed to foster an environment that fosters a positive view of the profession and promotes a positive attitude towards individuals and the profession.
Journal ArticleDOI
Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial
Marie Claude Morice,Patrick W. Serruys,A. Pieter Kappetein,Ted Feldman,Elisabeth Ståhle,Antonio Colombo,Michael J. Mack,David R. Holmes,Lucia Torracca,Gerrit Anne van Es,Katrin Leadley,Keith D. Dawkins,Friedrich W. Mohr +12 more
TL;DR: Patients with LM disease who had revascularization with PCI had safety and efficacy outcomes comparable to CABG at 1 year; longer follow-up is required to determine whether these 2 revascularized strategies offer comparable medium-term outcomes in this group of complex patients.
Journal ArticleDOI
Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial
Marie Claude Morice,Patrick W. Serruys,A. Pieter Kappetein,Ted Feldman,Elisabeth Ståhle,Antonio Colombo,Michael J. Mack,David R. Holmes,James W. Choi,Witold Rużyłło,Grzegorz Religa,Jian Huang,Kristine Roy,Keith D. Dawkins,Friedrich W. Mohr +14 more
TL;DR: This analysis compares 5-year clinical outcomes in PCI- and CABG-treated LM patients in the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) trial and suggests that both treatments are valid options for LM patients.